Drug Profile

JHU 083

Alternative Names: JHU083

Latest Information Update: 05 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Johns Hopkins University
Developer AstraZeneca
Class Antineoplastics; Azo compounds; Norleucines; Small molecules
Mechanism of Action Glutamine inhibitors; Granulocyte-macrophage colony-stimulating factor expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Jun 2024 JHU 083 is still in preclinical development for Cancer in USA
01 Jun 2024 Pharmacodynamics data from preclinical studies in Cancer presented at the 114th Annual Meeting of the 106th Annual Meeting of the Endocrine Society (ENDO-2024)
28 May 2024 No recent reports of development identified for preclinical development in Cancer in USA (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com